Jason Mast

The American Hospital Association and several hospital systems are suing the Trump Administration over an upcoming 340B pilot program

Novo Nordisk’s weight loss drug semaglutide failed to slow the progression of Alzheimer’s disease in two large trials

Johnson & Johnson said it will purchase Halda Therapeutics, marking the first major buyout for a cancer drugmaker built around so-called PROTACs, a buzzy new technology.

Marty Makary and Vinay Prasad offered a roadmap for expanding access to custom gene-editing treatments like the one used to treat Baby KJ's ultra-rare disease.

Exclusive: Arena Bioworks, the buzzy research institute that launched with $500 million to support a decade of scientific R&D, is abruptly shutting down, STAT has learned.

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer fighters with a single shot.

Exclusive: The inside story of why Moderna now faces a crisis unlike any in its 15-year-history.

BridgeBio said an experimental therapy for a rare form of muscular dystrophy succeeded in a key trial, potentially setting up the first drug approval in the disease. 

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage study, the company announced Tuesday.